Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits.
The efficacy of intravenously administered liposomal amphotericin B (AmBisome [AmBi]) for the treatment of experimental coccidioidal meningitis was compared with those of oral fluconazole (FLC) and intravenously administered conventional amphotericin B (AMB). Male New Zealand White rabbits were infected by intracisternal inoculation of arthroconidia of Coccidioides immitis. Starting 5 days postinfection, animals received one of the following: 5% dextrose water diluent; AMB given at 1 mg/kg of body weight; AmBi given at 7.5, 15, or 22.5 mg/kg intravenously three times per week for 3 weeks; or oral FLC given at 80 mg/kg for 19 days. One week after the cessation of therapy, all survivors were euthanatized, the numbers of CFU remaining in the spinal cord and brain were determined, and histological analyses were performed. All AmBi-, FLC-, or AMB-treated animals survived and had prolonged lengths of survival compared with those for the controls (P < 0.0001). Treated groups had significantly lower numbers of white blood cells and significantly lower protein concentrations in the cerebrospinal fluid compared with those for the controls (P < 0.01 to 0.0005) and had fewer clinical signs of infection (e.g., weight loss, elevated temperature, and neurological abnormalities including motor abnormalities). The mean histological scores for AmBi-treated rabbits were lower than those for FLC-treated and control rabbits (P < 0.016 and 0.0005, respectively); the scores for AMB-treated animals were lower than those for the controls (P < 0.0005) but were similar to those for FLC-treated rabbits. All regimens reduced the numbers of CFU in the brain and spinal cord compared with those for the controls (P < or =0.0005). AmBi-treated animals had 3- to 11-fold lower numbers of CFU than FLC-treated rabbits and 6- to 35-fold lower numbers of CFU than AmB-treated rabbits. Three of eight animals given 15 mg of AmBi per kg had no detectable infection in either tissue, whereas other doses of AmBi or FLC cleared either the brain or the spinal cord of infection in fewer rabbits. In addition, clearance of the infection from both tissues was achieved in none of the rabbits, and neither tissue was cleared of infection in AMB-treated animals. Overall, these data indicate that intravenously administered AmBi is superior to oral FLC or intravenous AMB and that FLC is better than AMB against experimental coccidioidal meningitis. These data indicate that AmBi may offer an improvement in the treatment of coccidioidal meningitis. Additional studies are warranted.
Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, California Institute for Medical Research, 751 South Bascom Avenue, San Jose, CA 95128, USA. clemons@cimr.org
Karl V
KV
Clemons
Raymond A
RA
Sobel
Paul L
PL
Williams
Demosthenes
D
Pappagianis
David A
DA
Stevens
D000666:Amphotericin B / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001831:Body Temperature; D001835:Body Weight; D001921:Brain / Q000382:microbiology; D002555:Cerebrospinal Fluid / Q000166:cytology; D003047:Coccidioidomycosis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000382:microbiology; D007958:Leukocyte Count; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000382:microbiology; D009043:Motor Activity; D011187:Posture; D011817:Rabbits; D013116:Spinal Cord / Q000382:microbiology; D016019:Survival Analysis
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B